<DOC>
	<DOCNO>NCT02806830</DOCNO>
	<brief_summary>In study , ocular discomfort follow intravitreal injection naïve patient study , well efficacy wet agent ( Optive eyewash ) prevent ocular discomfort .</brief_summary>
	<brief_title>Ocular Discomfort Assessment After Intravitreal Injections</brief_title>
	<detailed_description>In naive patient , two first intravitreal injection study . Within first injection , wet agent deliver . Within 72hours first intravitreal injection , patient contact phone nurse complete questionnaire quality life ocular pain eye discomfort . After second injection , treatment wet agent prescribe . With 72hours second injection , quality life , ocular discomfort well acceptability tolerance eye drop also assess phone questionnaire .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Retinal Artery Occlusion</mesh_term>
	<mesh_term>Myopia , Degenerative</mesh_term>
	<criteria>Patient 18 year old Patient social healthcare Patient understand French language Patient require antiVEGF treatment intravitreal injection Patient treat Ozurdex® Patient know treat ocular dryness Non naive patient intravitreal injection Hypersensitivity Carmellose Patient receive wet agent within 3 last month History povidoneiodine allergy Pregnant breastfeeding mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Intravitreal injection</keyword>
	<keyword>AMD</keyword>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Retinal Artery Occlusion</keyword>
	<keyword>Myopia , Degenerative</keyword>
	<keyword>eye drop</keyword>
</DOC>